To be honest I am surprised it’s not down further. On 23 Jan they forecast revenue of $18-23m for FY17, less than 4 months later that’s turned into $11-14. Given they had $6.4 in the bag, the downgrade for 2H is from $11.6–16.6m to $4.6-7.6m. They have expenses at $20-22m and maybe a touch over $5m cash – they are in trouble without a large capital injection or lifeline from a t/o.
- Forums
- ASX - By Stock
- AVA
- Ann: FY2017 Update and revised guidance
Ann: FY2017 Update and revised guidance, page-10
Featured News
Add AVA (ASX) to my watchlist
(20min delay)
|
|||||
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.71M |
Open | High | Low | Value | Volume |
13.0¢ | 13.5¢ | 13.0¢ | $18.25K | 137.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 55950 | 12.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 3554 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 55950 | 0.125 |
4 | 124041 | 0.120 |
2 | 243478 | 0.115 |
2 | 105454 | 0.110 |
2 | 80000 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.130 | 3554 | 1 |
0.135 | 286624 | 3 |
0.140 | 149132 | 4 |
0.145 | 81004 | 3 |
0.150 | 233943 | 5 |
Last trade - 14.25pm 13/11/2024 (20 minute delay) ? |
Featured News
AVA (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online